Thu. 4 Apr 2024, 6:32am ET
Benzinga
Biotech, News, Health Care, General
- Improved VELOS manufacturing process delivering higher cNeT doses.
- Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024.
- First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment.